CUMYL-PEGACLONE

CUMYL-PEGACLONE (SGT-151) is a gamma-carboline based synthetic cannabinoid that has been sold as a designer drug.^{[3][4][5][6][7][8]} The gamma-carboline core structure seen in CUMYL-PEGACLONE had not previously been encountered in a designer cannabinoid, though it is similar in structure to other gamma-carboline cannabinoids disclosed by Bristol-Myers Squibb in 2001.^[9][10][11]

CUMYL-PEGACLONE

Legal status
Legal status	BR: Class F2 (Prohibited psychotropics)[1] CA: Schedule II DE: Anlage II (Authorized trade only, not prescriptible) UK: Under Psychoactive Substances Act UN: Psychotropic Schedule II[2]
Identifiers
IUPAC name 2,5-Dihydro-2-(1-methyl-1-phenylethyl)-5-pentyl-1H-pyrido[4,3-b]indol-1-one
CAS Number	2160555-55-3
PubChem CID	134818034
ChemSpider	68003813
UNII	CUT2RV7EIQ
KEGG	C22782
Chemical and physical data
Formula	C25H28N2O
Molar mass	372.512 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(C1=CC=CC=C1)(C)N2C=CC(N(CCCCC)C3=C4C=CC=C3)=C4C2=O
InChI InChI=1S/C25H28N2O/c1-4-5-11-17-26-21-15-10-9-14-20(21)23-22(26)16-18-27(24(23)28) Key:AWHWTKXMUJLSRM-UHFFFAOYSA-N

Legal status

Sweden's public health agency classified CUMYL-PEGACLONE as a narcotic substance, on January 18, 2019.^[12]

In the United States, the DEA has temporarily placed CUMYL-PEGACLONE into Schedule I status starting on December 12th, 2023 for up to 2 years, during which it's possible the DEA could file for permanent scheduling within those 2 years. If the DEA does not file for permanent placement the temporary Schedule I order will expire on December 12th, 2025.^[13]

See also

• 5F-CUMYL-PEGACLONE
• CUMYL-CB-MEGACLONE
• CUMYL-CH-MEGACLONE
• CUMYL-BC-HPMEGACLONE-221
• CUMYL-PINACA
• CUMYL-5F-P7AICA
• UR-12